Research-use compounds studied in growth hormone axis and endocrine signalling models. Supplied for in-vitro laboratory research only; not for human or veterinary use.
The first selective growth hormone secretagogue that stimulates GH release without affecting ACTH, cortisol, or prolactin levels, investigated for bone health, muscle preservation, and gastrointestinal recovery.
- Purity tested
A truncated kisspeptin neuropeptide that potently activates KISS1R, serving as a key regulator of the hypothalamic-pituitary-gonadal axis with applications in reproductive endocrinology research.
- Purity tested
A modified fragment of human growth hormone (residues 176-191) investigated for its lipolytic properties, cartilage regeneration potential, and favorable safety profile without effects on blood glucose or IGF-1 levels.
- Purity tested
- Endotoxin tested
A truncated GHRH analogue (Modified GRF 1-29) with enhanced stability and prolonged half-life, supporting growth hormone release with shorter duration than the DAC variant.
- Purity tested
- Endotoxin tested
A modified GHRH analogue featuring a Drug Affinity Complex for extended half-life, producing sustained GH and IGF-1 elevations while preserving physiological pulsatility.
- Purity tested
A modified IGF-1 with extended half-life and enhanced potency due to reduced IGFBP binding, valuable for cell proliferation, muscle biology, and metabolic signaling research.
- Purity tested
A synthetic GHRH analogue (1-44) with FDA approval for HIV-associated lipodystrophy, investigated for visceral fat reduction, hepatic steatosis, and cognitive function enhancement.
- Purity tested
- Endotoxin tested